Медикаментозная профилактика рака предстательной железы. Исследование PCPT. Анализ отдаленных результатов

1. Klein E.A., Thompson I.M., Klein E.A. et al. Update on chemoprevention of prostate cancer. Curr Opin Urol 2004;14:143—9.

2. Isaacs J.T. Control of cell proliferation and cell death in the normal and neoplastic prostate: a stem cell model. In: C.H. Rodgers, D.S. Coffy, G.R. Cunha et al. (eds) Benign prostatic hyperplasia II. NIH Publ. No 87—2881, US dept. Health, Human Serv. Bethesda: NIH; 1987. p. 85—94.

3. Cabot A. The question of castration for enlarged prostate. Ann Serg 1896;24:256.

4. Huggins C., Hodges C.V. Studies of prostate cancer: I. The effect of castration on advanced carcinoma of the prostate gland. Arh Surg 1941;43:209.

5. Сивков А.В., Ощепков В.Н. Фармакотерапия доброкачественной гиперплазии и рака предстательной железы. Финастерид: 20 лет клинической практики лечения больных аденомой предстательной железы. Consilium Medicum 2006;08(4):36–9.

6. Gormely G.J., Brawley O., Thompson I. The potential application of finasteride for chemoprevention of prostate cancer. Ann N Y Acad Sci 1995;768:163.

7. Thompson I.M., Goodman P.J., Tangen C.M. et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215—24.

8. Gormley G.J., Stoner E., Bruskewitz R.C. et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327(17):1185—91.

9. Etzioni R.D., Howlader N., Shaw P.A. et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 2005;174(3):877—81.

10. Thompson I.M., Tangen C.M., Goodman P.J. et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294:2996—3002.

11. Thompson I.M., Pauler D.K., Goodman P.J. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4,0 ng per milliliter. N Engl J Med 2004;350:2239—46.

12. Carver B.S., Kattan M.W., Scardino P.T. et al. Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int 2005;95:509—12.

13. Civantos F. et al. Finasteride effect on prostatic hyperplasia and prostate cancer. J Urol Pathol 1997;6:1—13.

14. Bostwick D.G. et al. Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy. Urol Clin North Am 1999;26:465—79.

15. Yang X.J. et al. Does long-term finasteride therapy affect the histologic features of benign prostate tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar longterm efficacy and safety study. Urology 1998;53:696—700.

16. Rubin M.A., Allory Y., Molinie V. et al. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology 2005;66:930—4.

17. Bautista O.M. et al. Study desine of the medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials 2003;24:224.

18. Andriole G.L., Roehborn C., Schulman C. et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004;64:537.

19. Ishikawa S., Soloway M.S., van der Zwaag R. et al. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989;141(5):1139—42.

20. Raivio T., Santti H., Schatzl G. et al. Reduced circulating androgen bioactivity in patients with prostate cancer. Prostate 2003;55(3):194—8.

21. Thompson I.M., Klein E.A., Lippman S.M. et al. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 2003;44(6):650—5.

22. Marberger M., Adolfsson J., Borkowski A. et al. The clinical implications of the prostate cancer prevention trial. BJU Int 2003;92(7):667—71.

23. Roehrborn C.G. Prevention of prostate cancer with finasteride. N Engl J Med 2003;349:1569—72.

24. Djavan B., Zlotta A., Schulman C. et al. Chemotherapeutic prevention studies of prostate cancer. J Urol 2004;171(2 Pt 2):S10—3.

25. Algaba F., Epstein J.I., Aldape H.C. et al. Workgroup 5: Assessment of prostate carcinoma in core needle biopsy — definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer 1996;78: 376—81.

26. Bostwick D.G., Qian J., Civantos F. et al. Does finasteride alter the pathology of the prostate and cancer grading? Clin Prostate Cancer 2004;2:228—35.

27. Canby-Haginoa E., Hernandezb J., Branda T.C., Thompson I. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. Eur Urol 2007;51(1):27—33.

28. Klein E.A., Thompson I.M., Klein E.A., Thompson I.M. Update on chemoprevention of prostate cancer. Curr Opin Urol 2004;14:143—9.

29. Gomella L.G. Chemoprevention using dutasteride: the REDUCE trial. Curr Opin Urol 2005;15:29—32.